Quick Answer
Kalaris Therapeutics, Inc. reported Net Income Loss of -$43.44 million for the year ending 2025.
- Kalaris Therapeutics, Inc. showed an increase of +37.2% in Net Income Loss from 2024 to 2025.
- This data is from Kalaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Kalaris Therapeutics, Inc.'s Net Income Loss has declined by 82.2%.
- Historical annual values: Fiscal year 2025: -$43.44 million | Fiscal year 2024: -$69.17 million | Fiscal year 2023: -$190.42 million | Fiscal year 2022: -$168.71 million | Fiscal year 2021: -$171.96 million | Fiscal year 2020: -$69.78 million | Fiscal year 2019: -$23.84 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: